Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Zutphen – page 10

842 clinical trials in Zutphen, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Zutphen at a glance
842
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

842 trials in Zutphen

Open in trial search

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tafasitamab
  • Sponsor:Incyte Corp.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study Testing Atumelnant Compared to Placebo in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Steroid Dose While Controlling Hormones

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

A Study of Atumelnant for Children with Congenital Adrenal Hyperplasia

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Endometrial cancer+3

Recruiting

Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Zutphen

What the registry says about research in the country

01 Respiratory Diseases

Clinical research focusing on respiratory conditions including innovative treatments for asthma and viral infections. Studies encompass evaluation of new vaccine combinations and safety assessments of inhalation devices.

  • RSV and COVID-19 vaccine co-administration
  • Moderate to severe asthma treatments
  • Chronic Obstructive Pulmonary Disease management
  • Bronchiectasis therapy

Investigations include both preventive measures and therapeutic interventions for respiratory conditions.

02 Cardiovascular Studies

Comprehensive research into cardiovascular health, examining treatments for various heart conditions and prevention of major cardiac events.

  • Atherosclerotic Cardiovascular Disease
  • Heart Failure Management
  • Post-Heart Attack Treatment
  • Acute Coronary Syndrome

Focus on innovative therapies and interventions to improve patient outcomes in heart-related conditions.

03 Oncology Research

Advanced studies in lung cancer treatment and innovative therapeutic approaches for various cancer types.

  • Non-Small Cell Lung Cancer therapies
  • Immunotherapy optimization
  • Mantle Cell Lymphoma treatment

Evaluating novel treatment combinations and immunotherapy approaches for better patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.